View Post

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com Given the number of prophylactic interventions that are now available, counseling patients with early-stage HER2-positive breast cancer on the benefit of extended adjuvant therapy with neratinib (Nerlynx) or considering its use in those with central nervous system metastases could be beneficial, said Michel Velez, MD. “We know that neratinib has value in the extended adjuvant …

View Post

Dr. Carcas on the Design and Findings of CONTROL Trial in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Lauren Carcas, MD From: onclive.com Lauren Carcas, MD, medical oncologist, Miami Cancer Institute, Baptist Health South Florida, discusses the design of the CONTROL trial and her personal experience with prophylaxis interventions for women with early-stage HER2-positive breast cancer receiving neratinib (Nerlynx). The phase II CONTROL trial looked at how to control early-onset diarrhea within the first 2 cycles of …